Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 7

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 7
---
. Any of these factors may prevent us from completing our preclinical studies and clinical trials that we may initiate or from commercializing
any product candidates we may develop on a timely or profitable basis, if at all. In addition, the success of our Alpha DaRT technology
will depend on several factors, including the following:

  establishing manufacturing capabilities and infrastructure to produce and distribute adequate supply of Alpha DaRT sources in compliance with applicable regulations governing the transport of r...  

  generating meaningful clinical data to support widespread clinical adoption and reimbursement for the Alpha DaRT technology;  

  educating medical personnel regarding the potential benefits and correct use of our Alpha DaRT technology;  

  ensuring appropriate methods of handling and logistics of our products and appropriate capabilities at clinical use points;  

  facilitating patient access to the facilities able to administer our Alpha DaRT technology, if authorized for sale or certified;  

  establishing sales and marketing capabilities upon obtaining any marketing authorization in the United States and similar authorization or certification in other target jurisdictions to gain ma...  

  sourcing clinical and, if successfully authorized or certified for commercial sale, commercial supplies for the materials used to manufacture our Alpha DaRT technology, and especially our Alpha...  

The commercial success of our Alpha DaRT
technology, if authorized or certified for commercial sale, will depend in part upon public perception of radiation therapies, and to
a lesser extent, radiopharmaceuticals, and the degree of their market acceptance by physicians, patients, healthcare payors and others
in the medical community.

Adverse events in clinical
trials of our Alpha DaRT technology or in clinical trials of others developing similar products and the resulting negative publicity,
as well as any other adverse events in the field of radiation therapies or radiopharmaceuticals that may occur in the future, could result
in a decrease in demand for our Alpha DaRT technology or any future products or any product candidates that we may develop that rely on
radiation therapy. If public perception is influenced by claims that radiation therapies or radiopharmaceuticals or specific therapies
within radiation therapies or radiopharmaceuticals are unsafe or if alternative therapies for cancer treatment are developed and proven
to be more successful or provide an actual or perceived, preferred course of treatment for cancer(s), our Alpha DaRT technology or any
future products or any product candidates we may develop may not be accepted by the general public or the medical community.

In particular, the future
commercial success of our Alpha DaRT technology or any future products or any product candidates we may develop